Marc-Olivier Geinoz Confirmed as Chairman
and Elected Chief Executive Officer of the Company
Milan, Italy – Dipharma Francis S.r.l., (Dipharma), a global Contract Development and Manufacturing Organization (CDMO) and leading manufacturer of New Chemical Entities (NCE), Generic Active Pharmaceutical Ingredients and Advanced Intermediates, announced today, May 22nd, 2024, that the Shareholder’s Meeting appointed the new Board of Directors, which subsequently appointed a new Chief Executive Officer.
Effective as of today, the new Board of Directors will be composed by:
- Marc-Olivier Geinoz, who has been confirmed as Chairman of the Company and appointed as the new Chief Executive Officer.
- Marco Magnani, who has been confirmed as non-Executive Director.
- Enrico Polastro, who has been confirmed as non-Executive Director.
Dipharma Francis S.r.l. expresses its sincerest thanks to Jorge Nogueira, who has held the position of CEO over the past years, for his contributions to company’s development, and wishes the Board of Directors continued success in seizing new opportunities and facing the challenges ahead towards a successful future.
About the new BoD members
Marc-Olivier Geinoz, MBA, Chairman of Socorex Holding S.A., CEO of Dipharma Francis S.r.l. from 2005 to 2019 and Chairman since 2019.
Marco Magnani, Economist, professor of International Economics at Luiss in Rome and Università Cattolica in Milan, Senior Research Fellow at the Harvard Kennedy School. Previously, investment banker at JP Morgan in New York and Mediobanca in Milano.
Enrico Polastro, PhD and MBA, member of Dipharma Francis S.r.l. Board of Directors since 1997. Extensive experience in the Chemical and Pharmaceutical industry through his career as top management consultant with an international firm.
About the Dipharma Francis group
With revenues of €160 million, the Dipharma Group is a global CDMO and a leading manufacturer of APIs and Intermediates, with about 600 skilled and highly committed employees, 4 cGMP plants, located in the U.S.A. and Italy, plus sales offices in Italy, the U.S.A. and China. The fully equipped R&D Centers develop innovative chemical processes and crystalline forms for the most prominent pharmaceutical companies worldwide. As a third-generation family-owned company, Dipharma has a long history of stability, commitment, and financial solidity. Dipharma has the right size and variety of scale-up capabilities to act as a global player and manage processes efficiently, while offering flexibility and agility to promptly solve any challenge.
Experience you can trust
For more information:
Paola Clerici
Communication Manager
Dipharma Francis S.r.l.
E-mail: paola.clerici@dipharma.com
